Conquering Diseases

A Study Looking At A New Drug For Treatment Of Stroke In Addition To Standard Treatments (Fastest)

Description

Seeking men and women 18 years of age or older who have had a stroke caused by bleeding in their brain to help determine is a new drug called recombinant factor VIIa (rFVIIa) can improve outcomes compared to a placebo when added to the standard care provided after a stroke.

Overview

This study is being conducted to see if a medicine used to treat and prevent bleeding improves outcomes after a stroke caused by bleeding in the brain. The medicine is called Recombinant Factor VIIa (rFVIIa). Participants in this study will receive either the medicine or a placebo that contains no active medications.

What we're hoping for

To determine if treatment with Recombinant Factor VIIa (rFVIIa) works better than a placebo to improve participants outcome after a stroke

Additional Information

ClinicalTrials.gov Identifier: NCT03496883

 Principal Investigator

Adalia  Jun-O'Connell, MD

University of Massachusetts Medical School

 Study Contact

Beshoy  Armanios

Beshoy.Armanios@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989